title: Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis.
abstract: BACKGROUND
  Following bile duct ligation (BDL) endogenous opioids accumulate in plasma and play a role in the pathophysiology and manifestation of cholestasis. Evidence of centrally mediated induction of liver injury by exogenous opioid agonist administration, prompts the question of whether opioid receptor blockade by naltrexone can affect cholestasis-induced liver injury.
  
  
  METHODS
  Cholestasis was induced by BDL and cholestatic and sham-operated rats received either naltrexone or saline for 7 consecutive days. On the 7th day, liver samples were collected for determining matrix metalloproteinase-2 (MMP-2) activity, S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) content and blood samples were obtained for measuring plasma nitrite/nitrate and liver enzyme activities.
  
  
  RESULTS
  Naltrexone-treated BDL animals had a significant reduction in plasma enzyme activity and nitrite/nitrate level. Liver SAM : SAH ratio and SAM level improved by naltrexone treatment in cholestatic animals compared to saline-treated BDL ones. Naltrexone treatment in BDL rats led to a decrease in the level of liver MMP-2 activity, which had already increased during cholestasis.
  
  
  CONCLUSIONS
  Opioid receptor blockade improved the degree of liver injury in cholestasis, as assessed by plasma enzyme and liver MMP-2 activities. The beneficial effect of naltrexone may be due to its ability to increase liver SAM level and restore the SAM : SAH ratio.
authors.affiliation: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samira
authors.initials: S
authors.lastname: Kiani
authors.forename: Mohammad R
authors.initials: MR
authors.lastname: Ebrahimkhani
authors.forename: Ahmad
authors.initials: A
authors.lastname: Shariftabrizi
authors.forename: Behzad
authors.initials: B
authors.lastname: Doratotaj
authors.forename: Seyedmehdi
authors.initials: S
authors.lastname: Payabvash
authors.forename: Kiarash
authors.initials: K
authors.lastname: Riazi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Dehghani
authors.forename: Hooman
authors.initials: H
authors.lastname: Honar
authors.forename: Alaleh
authors.initials: A
authors.lastname: Karoon
authors.forename: Massoud
authors.initials: M
authors.lastname: Amanlou
authors.forename: Seyed M
authors.initials: SM
authors.lastname: Tavangar
authors.forename: Ahmad R
authors.initials: AR
authors.lastname: Dehpour
mesh_terms: D000818:Animals; D002779:Cholestasis / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology*; D017364:Collagenases / Q000378:metabolism*; D004195:Disease Models, Animal; D008107:Liver Diseases / Q000097:blood / Q000201:enzymology* / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D009292:Narcotic Antagonists; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D009292:Narcotic Antagonists; D017364:Collagenases